Data Highlights Clinical Utility of CareDx Solutions, Including Findings from
CareDx Symposia Feature Latest Advancements Including XenoSure and XenoMap
“CareDx is proud of its history of innovation in cardiothoracic transplantation, with many firsts, from multimodality molecular assessment of allograft health, to donor-derived cell-free DNA for lung transplantation, to recently introducing, XenoSure™ and XenoMap™, for investigational use in xenotransplantation research,” said
“The initial findings from the SHORE study build upon a growing literature that supports non-invasive surveillance of heart transplant patients with AlloSure donor-derived cell-free DNA and AlloMap gene-expression profiling. These studies provide a more comprehensive assessment of the health of the transplanted heart, which will hopefully lead to better outcomes for our patients through more tailored management strategies and earlier detection of graft injury,” said Dr.
CareDx Lunch Symposia:
- Changing the Paradigm of Heart Transplant Surveillance with HeartCare,
Wednesday, April 27 , 12–1 PM EDT - Advancing Care in Lung Transplantation: The Past, the Present and the Future,
Thursday, April 28 , 12:15–1:15 PM EDT
For more detailed agendas for the lunch symposia, please follow this link.
The following heart and lung transplant data will be presented:
Title | Author/Presenter | Type |
Heart Transplant | ||
Beyond the Surface: | Dr. | Symposium |
Putting It All Together: Integrating Approaches for Rejection Assessment | Dr. | Symposium |
Low AlloSure® In HeartCare® Associated With Low Risk of Significant Allograft Rejection: An Analysis Of SHORE | Dr. | Oral Presentation |
Should We Be Comforted By A “Negative” Endomyocardial Biopsy? Risk Of Future Events With Donor-Derived Cell Free DNA In The Setting Of Histologic Quiescence | Dr. | Oral Presentation |
Prognostic Implications And Characteristics Of Low dd-cfDNA Results In Heart Transplant Patients With Biopsy Proven Rejection | Dr. | Oral Presentation |
Impact on Donor-Derived Cell-Free DNA (dd-cfDNA) of Procurement Using Paragonix Sherpapak™ (SP) Cardiac Transport System vs. Ice Transportation | Dr. | Oral Presentation |
Relationship of Non-Invasive Detection of Allograft Rejection and Injury (Donor-Derived Cell Free DNA and Gene Expression Profiling) and Tissue-Based Molecular Microscopic Diagnosis After Heart Transplantation | Dr. | Oral Presentation |
The Gut Microbiome as a Marker of Early Cardiac Allograft Injury | Dr. | Oral Presentation |
Hepatitis C Donors Are Not Associated With Higher Rates Of Rejection After Cardiac Transplantation | Dr. Assi Milwidsky | Oral Presentation |
Effect Of CMV Viremia On HeartCare | Dr. | Oral Presentation |
Using Donor-Derived Cell-Free DNA for Assessment of Myocardial Injury in Heart Transplant Recipients After SARS-CoV2 Infection | Dr. | Oral Presentation |
Effect Of COVID-19 Infection On HeartCare, Data From The SHORE Multicenter Registry | Dr. | Mini-Oral Presentation |
Artificial Intelligence 12 Lead ECG Based Heart Age Estimation and 1-year Outcomes After Heart Transplantation | Dr. | Poster |
Variability in Donor-Derived Cell-Free DNA Levels Predicts Mortality Risk in Heart Transplant Recipients | Dr. | Poster |
Impact Of Donor Characteristics On AlloSure Scores | Dr. | Poster |
Use of Donor Derived Cell Free DNA for Long Term Rejection Surveillance in OHT Recipients | Dr. Swethika Sundaravel | Poster |
Early Use of Donor Derived Cell-Free DNA (dd-cfDNA) in Heart Transplantation | Dr. | Poster |
Prevalence of Clinical Events Following High Donor Derived Cell Free DNA in the Absence of Rejection in Heart Transplant Recipients | Dr. | Poster |
Is Absolute Change In AlloMap More Informative Than Absolute Value? | Dr. | Poster |
Donor Specific Allo-Antibody is Significantly Associated With Variability in Donor-Derived Cell-Free DNA Scores in Adult Heart Transplant Recipients | Dr. | Poster |
Don’t Take Another Piece of My Heart: Substantial Reduction in Biopsies with Initiation of Non-Invasive Rejection Surveillance at One Month Post-Transplant | Dr. | Poster |
Utility of AlloMap® Scores in Younger Pediatric Heart Transplant Recipients | Dr. Laura D’Addese | Poster |
Lung Transplant | ||
Performance of Donor-Derived Cell-Free DNA (dd-cfDNA) for Discriminating Acute Lung Allograft Injury in a Multicenter Cohort | Dr. | Oral Presentation |
Higher Levels of Donor Derived Cell Free DNA are Associated with Acute Cellular Rejection but Not with Severe PGD after Lung Transplantation | Dr. | Oral Presentation |
Donor-Derived Cell-Free DNA Plus Tissue Gene Expression Profiling of Lung Allograft Injury | Dr. | Oral Presentation |
Bronchoalveolar Lavage Fluid (BALF) as a Compartment for Donor-Derived Cell-Free DNA (dd-cfDNA) Assessment in Lung Recipients | Dr. | Mini-Oral Presentation |
dd-cfDNA levels are independent of Allograft Longevity inStable lung Recipients | Dr. | Mini-Oral presentation |
Longitudinal Monitoring of Donor Derived Cell Free DNA in Lung Transplant Recipients | Dr. | Poster |
About
Forward Looking Statements
This press release includes forward-looking statements related to
CONTACTS:
Chief Marketing Officer
415-287-2393
sking@caredx.com
Investor Relations
(415) 722-4563
investor@CareDx.com
Source:
2022 GlobeNewswire, Inc., source